Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction

Launched by HEBEI MEDICAL UNIVERSITY · Oct 10, 2013

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Disease must be clinically limited to the esophagogastric junction, defined TypeⅡ TypeⅢ(From the endoscopic point of view according to the AEG criteria)
• • 2. Histologically confirmed primary adenocarcinoma
• • 3. T2-4 N0-3 M0. T1 tumors are eligible if T1N1-3M0，
• • 4. ECOG performance status ≦2
• • AEG is defined and described as tumors which have their center within 5cm proximal or distal of the anatomical cardia.
• • The classification of AEG type I, type II and type III AEG type I: adenocarcinoma of the distal esophagus,which usually arises from an area with specialized intestinal metaplasia of the esophagus, i Barrett's esophagus, and may infiltrate the esophago-gastric junction from above;
• • AEG type II: true carcinoma of the cardia, arising from the cardia epithelium or short segments with intestinal metaplasia at the esophago-gastric junction;
• • AEG type III: subcardial gastric carcinoma, which infiltrates the esophago-gastric junction and distal esophagus from below.
• Exclusion Criteria:
• • 1. Tis (in-situ carcinoma) and tumors determined to be TIN0 following endoscopy, endoscopic ultrasound and CT scanning.
• • 2. Patients with primary carcinomas of the esophagus.
• • 3. Prior chest or upper abdomen radiotherapy, prior systemic chemotherapy within the past 5 years, or prior esophageal or gastric surgery.
• • 4. Patients with evidence of metastatic disease are not eligible.
• • 5. Patients with a history of seizure disorder who are receiving phenytoin, phenobarbital, or other antiepileptic medication.
• • 6. Patients who cannot fully comprehend the therapeutic implications of the protocol or comply with its requirements.
• • 7. Patients with any medical or psychiatric condition or disease which, in the investigator's judgment, would make the patient inappropriate for entry into this study.
• • 8. History of hypersensitivity to fluoropyrimidines, capecitabine, oxaliplatin or the ingredients of this product -